H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued
August 08, 2014 at 09:24 AM EDT
In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $19.00 price target on Keryx ...